A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Inclusion Criteria:

• Histologically confirmed advanced solid tumor (measurable or nonmeasurable) that is potentially responsive to erlotinib or for which no effective therapy is available,
• Cohort 1: Adequate hepatic function: bilirubin <= ULN, ALT (SGPT) and AST (SGOT) <= 1.5 x ULN or Cohort 2: Moderate hepatic function: 7-9 as assessed by the Child-Pugh System, ECOG Performance Status 0-2
• Life expectancy >= 12 weeks,
• Prior radiation permitted provided that 4 weeks (or 2 weeks for palliative radiation) has elapsed and patients have recovered from acute toxic effects of radiotherapy,
• Prior chemotherapy permitted provided that 4 weeks has elapsed and patients have recovered from acute toxic effects of chemotherapy,
• Adequate hematopoietic and renal function: ANC >= 1.5 x 10^9/L, platelets >= 75 x 10^9/L, and creatinine <= 1.5 x ULN,

Exclusion Criteria:

• Use of tobacco or nicotine-containing products within 4 weeks of Day 1 and while on study,
• Use of a CYP3A4 inhibitor or inducer within 14 days prior to Day 1 and until Day 5,
• Use of a warfarin-derivative anticoagulant within 14 days prior to Day 1 and until Day 5,
• Encephalopathy >= grade 2,
• Significant history of cardiac disease unless well-controlled,
• Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation,
• Concurrent anticancer therapy or any other investigational agents within 4 weeks of Day 1 and while on study,
• Symptomatic brain metastases that are not stable, require steroids, are potentially life-threatening, or that have required radiation within the last 4 weeks,
• Gastro-intestinal abnormalities, including inability to take oral medication, requirement for IV alimentation, active peptic ulcer or prior surgical procedures affecting absorption.